Comparing the current results to its competitors, Interpace Biosciences Inc reported Revenue increase in the 2 quarter 2026 by 10.33 % year on year. The revenue growth was below Interpace Biosciences Inc 's competitors' average revenue growth of 11.3 %, achieved in the same quarter.
Interpace Biosciences Inc 's Comment on Competition and Industry Peers
The company competes based on reputation, scientific expertise, service quality, management experience, performance record, customer satisfaction, accessibility, flexibility, responsiveness to customer needs, integration skills, product portfolio, and price. Some competitors are substantially larger, with greater capital, personnel, and resources, broader product lines, and higher brand recognition. Rapid technological developments by competitors may render the company's technologies and products obsolete before recovering development expenses or generating significant revenue. Increased competition may result in pricing pressures and competitive practices that could materially adversely affect the company.
Overall company revenue, increased less, than total company revenues, at 10.33 % and lost market share, to approximately 0.26 %. << More on PDII Market Share.
*Market share is calculated based on total revenue.
Veracyte Inc's business model revolves around providing genomic diagnostic solutions to enable physicians to make more informed treatment decisions for patients.
Sources:
Interpace Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Interpace Biosciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
